PMID- 26573774
OWN - NLM
STAT- MEDLINE
DCOM- 20160930
LR  - 20190221
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 35
IP  - 2
DP  - 2016 Feb
TI  - Downregulation of Bmi-1 is associated with suppressed tumorigenesis and induced 
      apoptosis in CD44(+) nasopharyngeal carcinoma cancer stem-like cells.
PG  - 923-31
LID - 10.3892/or.2015.4414 [doi]
AB  - Bmi-1 (B-cell-specific Moloney murine leukemia virus insertion site 1) is a 
      member of the Polycomb group gene (PcG) family, which is involved in the 
      proliferation, migration and tumorigenesis of several types of cancer stem cells 
      (CSCs). However, its precise role and mechanism in CD44+ nasopharyngeal carcinoma 
      (NPC) cancer stem-like cells (CSC-LCs) remain poorly understood. In our previous 
      study, we successfully silenced Bmi-1 by short hairpin RNA (shRNA) in CD44+ NPC 
      CSC-LCs and obtained stable Bmi-1 knockdown (KD) cell lines. In the present 
      study, we tested the cell proliferation by CCK-8 assay and apoptosis by  fl ow 
      cytometry. Scratch wound healing assay, together with Transwell migration and 
      invasion assays were used to measure the migration and invasion capacity. We 
      further evaluated the tumorigenicity of CD44+ NPC CSC-LCs transfected with Bmi-1 
      shRNA in vivo. Based on our results, knockdown of Bmi-1 by shRNA resulted in the 
      inhibition of tumor proliferation, migration and invasion in vitro, followed by 
      cell apoptosis. In addition, our results preliminarily demonstrated that 
      inhibition of Bmi-1 expression by shRNA increased tumor apoptosis through the 
      p16INK4a-p14ARF-p53 pathway. Bmi-1 silencing in CD44+ NPC CSC-LCs also resulted 
      in the failure to develop tumors in vivo. These results provide important 
      insights into the role of Bmi-1 in the occurrence and development of NPC. Based 
      on our findings, regulation of Bmi-1 in CD44+ NPC CSC-LCs may provide a potential 
      molecular target for the therapy of NPC, and targeted silencing of Bmi-1 by shRNA 
      may have clinical future implications in NPC therapy.
FAU - Xu, Xinhua
AU  - Xu X
AD  - The First College of Clinical Medical Science, China Three Gorges University and 
      Department of Oncology, Yichang Central People's Hospital, Yichang, Hubei 443003, 
      P.R. China.
FAU - Liu, Yang
AU  - Liu Y
AD  - The First College of Clinical Medical Science, China Three Gorges University and 
      Department of Oncology, Yichang Central People's Hospital, Yichang, Hubei 443003, 
      P.R. China.
FAU - Su, Jin
AU  - Su J
AD  - Oncology Institute, China Three Gorges University, Yichang, Hubei 443003, P.R. 
      China.
FAU - Li, Daojun
AU  - Li D
AD  - Oncology Institute, China Three Gorges University, Yichang, Hubei 443003, P.R. 
      China.
FAU - Hu, Juan
AU  - Hu J
AD  - Oncology Institute, China Three Gorges University, Yichang, Hubei 443003, P.R. 
      China.
FAU - Huang, Qiao
AU  - Huang Q
AD  - Oncology Institute, China Three Gorges University, Yichang, Hubei 443003, P.R. 
      China.
FAU - Lu, Mingqian
AU  - Lu M
AD  - The First College of Clinical Medical Science, China Three Gorges University and 
      Department of Oncology, Yichang Central People's Hospital, Yichang, Hubei 443003, 
      P.R. China.
FAU - Liu, Xiaoyan
AU  - Liu X
AD  - The First College of Clinical Medical Science, China Three Gorges University and 
      Department of Oncology, Yichang Central People's Hospital, Yichang, Hubei 443003, 
      P.R. China.
FAU - Ren, Jinghua
AU  - Ren J
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, Hubei 430023, P.R. China.
FAU - Chen, Weihong
AU  - Chen W
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, Hubei 430023, P.R. China.
FAU - Sun, Lidan
AU  - Sun L
AD  - Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Department of 
      Medical College, China Three Gorges University, Yichang, Hubei 443002, P.R. 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151112
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (BMI1 protein, human)
RN  - 0 (CD44 protein, human)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (RNA, Small Interfering)
RN  - EC 2.3.2.27 (Polycomb Repressive Complex 1)
SB  - IM
MH  - Animals
MH  - Apoptosis/*physiology
MH  - Carcinogenesis/*metabolism
MH  - Carcinoma
MH  - Cell Line, Tumor
MH  - Cell Proliferation/physiology
MH  - Down-Regulation
MH  - Flow Cytometry
MH  - Gene Knockdown Techniques
MH  - Heterografts
MH  - Humans
MH  - Hyaluronan Receptors/metabolism
MH  - Immunohistochemistry
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Nasopharyngeal Carcinoma
MH  - Nasopharyngeal Neoplasms/metabolism/*pathology
MH  - Neoplastic Stem Cells/*metabolism
MH  - Polycomb Repressive Complex 1/*metabolism
MH  - RNA, Small Interfering
EDAT- 2015/11/18 06:00
MHDA- 2016/10/01 06:00
CRDT- 2015/11/18 06:00
PHST- 2015/07/16 00:00 [received]
PHST- 2015/09/29 00:00 [accepted]
PHST- 2015/11/18 06:00 [entrez]
PHST- 2015/11/18 06:00 [pubmed]
PHST- 2016/10/01 06:00 [medline]
AID - 10.3892/or.2015.4414 [doi]
PST - ppublish
SO  - Oncol Rep. 2016 Feb;35(2):923-31. doi: 10.3892/or.2015.4414. Epub 2015 Nov 12.